The advent of immune checkpoint inhibitors (ICIs), targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), has revolutionised cancer therapy, providing robust and durable responses in GC. Here, PDCD1 is linked to cancer.